{
    "2018-04-05": [
        [
            {
                "time": "2018-03-15",
                "original_text": "Lilly's Cyramza Shows Survival Benefit in Liver Cancer Study",
                "features": {
                    "keywords": [
                        "Cyramza",
                        "Survival Benefit",
                        "Liver Cancer",
                        "Study"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-10",
                "original_text": "FDA Refuses Alkermes Depression Drug Review: 4 Stocks in Focus",
                "features": {
                    "keywords": [
                        "FDA",
                        "Refuses",
                        "Alkermes",
                        "Depression Drug",
                        "Review"
                    ],
                    "sentiment_score": -0.65,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-03-15",
                "original_text": "Lilly's Cyramza Shows Survival Benefit in Liver Cancer Study",
                "features": {
                    "keywords": [
                        "Cyramza",
                        "Survival Benefit",
                        "Liver Cancer",
                        "Study"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-05-01",
                "original_text": "CNAT Disappoints, EBIO To Report VISTA Data In May, PRTK To Face FDA In Oct.",
                "features": {
                    "keywords": [
                        "CNAT",
                        "Disappoints",
                        "EBIO",
                        "VISTA Data",
                        "PRTK",
                        "FDA"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}